Cited by 196Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical TreatmentsIntraperitoneal and Appendiceal Malignancies

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

Pooled Safety and Efficacy Analysis Examining the Effect of Performance Status on Outcomes in Nine First-Line Treatment Trials Using Individual Data From Patients With Metastatic Colorectal Cancer

Open access

Sargent, Daniel J., Köhne, Claus Henning, Sanoff, Hanna Kelly, Bot, Brian M., Seymour, Matthew T., de Gramont, Aimery, Porschen, Ranier, Saltz, Leonard B., Rougier, Philippe, Tournigand, Christopher, Douillard, Jean-Yves, Stephens, Richard J., Grothey, Axel, Goldberg, Richard M.·2009·Journal of Clinical Oncology

DOI 10.1200/jco.2008.20.2879PMC PMC2669760

Open this paper in CoChat — free account

Abstract

Purpose: Performance status (PS) is a prognostic factor in patients with metastatic colorectal cancer. Clinical trials typically enroll less than 10% of patients with a PS of 2 (PS2); thus, the benefit of systemic chemotherapy in PS2 patients is uncertain. Patients and Methods: Individual data from 6,286 patients (509 PS2 patients) from nine clinical trials were used to compare treatment efficacy by PS. Progression-free survival (PFS), grade ≥ 3 adverse events, 60-day all-cause mortality, overall survival (OS), and response rate (RR) were explored in the full set of nine trials and in the five trials comparing first-line monotherapy with combination therapy. Results: Compared with patients with PS of 0 or 1, PS2 patients had significantly higher rates of grade ≥ 3 nausea (8.5% v 16.4%, respectively; P < .0001) and vomiting (7.6% v 11.9%, respectively; P = .006) and 60-day all-cause mortality (2.8% v 12.0%, respectively; P < .0001). PS2 was prognostic for PFS (hazard ratio [HR] = 1.52; P < .0001; median PFS, 7.6 months for PS 0 or 1 v 4.9 months for PS2), OS (HR = 2.18; P < .0001; median OS, 17.3 months for PS 0 or 1 v 8.5 months for PS2), and RR (odds ratio = 0.61; P < .0001; 43.8% for PS 0 or 1 v 32.0% for PS2). The relative benefit and toxicity of experimental versus control treatment and monotherapy versus combination therapy were not different in PS 0 or 1 patients versus PS2 patients. Conclusion: In clinical trials, PS2 patients derive similar benefit from superior treatment as patients with PS of 0 to 1 but with an increased risk of toxicities and 12% 60-day mortality. Although current treatment provides benefit, new approaches are required to approach 1-year median survival for PS2 patients.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1200/jco.2008.20.2879

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer
de Gramont, A., Figer, A., Seymour, M., Homerin, M., Hmissi, A., Cassidy, J., Boni, C., Cortes-Funes, H., Cervantes, A., Freyer, G., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.16.2938 · Cited by 3,815
Self-citation
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial
Douillard, J., Cunningham, D., Roth, A., Navarro, M., James, R., Karasek, P., Jandik, P., Iveson, T., Carmichael, J., Alakl, M., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02034-1 · Cited by 3,256
Self-citation
Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
Saltz, L. B., Cox, J. V., Blanke, C. D., Rosen, L. S., Fehrenbacher, L., Moore, M. J., Maroun, J. A., Ackland, S. P., Locker, P. K., Pirotta, N., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009283431302 · Cited by 3,004
Self-citation
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study
Tournigand, C., André, T., Achille, E., Lledo, G., Flesh, M., Mery-Mignard, D., Quinaux, E., Couteau, C., Buyse, M., Ganem, G., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.05.113 · Cited by 2,915
Self-citation
A Randomized Controlled Trial of Fluorouracil Plus Leucovorin, Irinotecan, and Oxaliplatin Combinations in Patients With Previously Untreated Metastatic Colorectal Cancer
Goldberg, R. M., Sargent, D. J., Morton, R. F., Fuchs, C. S., Ramanathan, R. K., Williamson, S. K., Findlay, B., Pitot, H. C., & Alberts, S. R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2004.09.046 · Cited by 2,251
Self-citation
Addition of Bevacizumab to Bolus Fluorouracil and Leucovorin in First-Line Metastatic Colorectal Cancer: Results of a Randomized Phase II Trial
Kabbinavar, F. F., Schulz, J. J., McCleod, M., Patel, T. N., Hamm, J. T., Hecht, J. R., MASS, R. D., Perrou, B., Nelson, B. J., & Novotny, W. F. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.112 · Cited by 933
Randomized, Controlled Trial of Irinotecan Plus Infusional, Bolus, or Oral Fluoropyrimidines in First-Line Treatment of Metastatic Colorectal Cancer: Results From the BICC-C Study
Fuchs, C. S., Marshall, J. L., Mitchell, E. P., Wierzbicki, R. F., Ganju, V., Jeffery, M., Schulz, J. J., Richards, D., Soufi‐Mahjoubi, R., Wang, B. X., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.3357 · Cited by 849

Show all 32 references

Research works printed but not linked: 3

Saltz L, 2007, J Clin Oncol, 25, 170s
10.1200/jco.2004.22.14_suppl.3565 · DOI
Van Cutsem E, 2007, J Clin Oncol, 25, 164s

Sorted by citations

Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Benson, A. B., Venook, A. P., Al-Hawary, M. M., Arain, M. A., Chen, Y., Ciombor, K. K., Cohen, S. A., Cooper, H. S., Deming, D. A., Farkas, L. M., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.0012 · Cited by 1,737
Self-citation
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A. E., ELIAS, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,612
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making
Schmoll, H., Cutsem, E. V., Stein, A., Valentini, V., Glimelius, B. L. G., Haustermans, K. M., Nordlinger, B., van de Velde, C. J., Balmañà, J., Reguła, J., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mds236 · Cited by 1,534
Self-citation
Colon Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology
Benson, A. B., Venook, A. P., Cederquist, L., Chan, E., Chen, Y., Cooper, H. S., Deming, D. A., Engstrom, P. F., Enzinger, P. C., Fichera, A., et al. (2017) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2017.0036 · Cited by 1,333
Self-citation
Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update
Masters, G. A., Temin, S., Azzoli, C. G., Giaccone, G., Baker, S., Brahmer, J. R., Ellis, P. M., Gajra, A., Rackear, N., Schiller, J. H., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.1342 · Cited by 850
Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial
Seymour, M., Thompson, L. C., Wasan, H. S., Middleton, G., Brewster, A. E., Shepherd, S. F., O'Mahony, M. S., Maughan, T., Parmar, M., & Langley, R. E. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60399-1 · Cited by 420
Self-citation
Colon cancer
Labianca, R., Beretta, G. D., Kildani, B., Milesi, L., Merlin, F., Mosconi, S., Pessi, M. A., Prochilo, T., Quadri, A., Gatta, G., et al. (2010) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2010.01.010 · Cited by 431
Five-Year Data and Prognostic Factor Analysis of Oxaliplatin and Irinotecan Combinations for Advanced Colorectal Cancer: N9741
Sanoff, H. K., Sargent, D. J., Campbell, M. E., Morton, R. F., Fuchs, C. S., Ramanathan, R. K., Williamson, S. K., Findlay, B., Pitot, H. C., & Goldberg, R. M. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.7147 · Cited by 304
Self-citation
Moving beyond Karnofsky and ECOG Performance Status Assessments with New Technologies
Kelly, C. M., & Shahrokni, A. (2016) · Journal of Oncology · doi:10.1155/2016/6186543 · Cited by 229
Body composition and sarcopenia: The next-generation of personalized oncology and pharmacology?
Hilmi, M., Jouinot, A., Burns, R. G., Pigneur, F., Mounier, R., Gondin, J., Neuzillet, C., & Goldwasser, F. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.12.003 · Cited by 145
Pre-treatment lymphopenia as a prognostic biomarker in colorectal cancer patients receiving chemotherapy
Cézé, N., Thibault, G., Goujon, G., Viguier, J., Watier, H., Dorval, E. D., & Lecomte, T. (2011) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-011-1610-3 · Cited by 141
Metastatic colorectal cancer (mCRC): French intergroup clinical practice guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SFR)
Phelip, J., Tougeron, D., Léonard, D., Benhaïm, L., Desolneux, G., Dupré, A., Michel, P., Penna, C., Tournigand, C., Louvet, C., et al. (2019) · Digestive and Liver Disease · doi:10.1016/j.dld.2019.05.035 · Cited by 148
Self-citation
Clinical trial enrollment, patient characteristics, and survival differences in prospectively registered metastatic colorectal cancer patients
Sørbye, H., Pfeiffer, P., Cavalli‐Björkman, N., Qvortrup, C., Holsen, M. H., Wentzel‐Larsen, T., & Glimelius, B. L. G. (2009) · Cancer · doi:10.1002/cncr.24527 · Cited by 134
Krabbamein í ristli og endaþarmi - yfirlitsgrein
Haraldsdóttir, S., Einarsdóttir, H. M., Smáradóttir, A., Gunnlaugsson, A., Halfdanarson, T. R., & Hálfdánarson, Þ. R. (2014) · Læknablaðið · doi:10.17992/lbl.2014.02.531 · Cited by 131
Resectability and Ablatability Criteria for the Treatment of Liver Only Colorectal Metastases: Multidisciplinary Consensus Document from the COLLISION Trial Group
Nieuwenhuizen, S., Puijk, R. S., van den Bemd, B. A. T., Aldrighetti, L. A., Arntz, M. J., van den Boezem, P. B., Bruynzeel, A. M. E., Burgmans, M. C., COBELLI, F. D., Coolsen, M. M. E., et al. (2020) · Cancers · doi:10.3390/cancers12071779 · Cited by 117
Balancing the efficacy and toxicity of chemotherapy in colorectal cancer
Braun, M. S., & Seymour, M. T. (2011) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834010388342 · Cited by 100
Self-citation
The G8 screening tool enhances prognostic value to ECOG performance status in elderly cancer patients: A retrospective, single institutional study
Takahashi, M., Takahashi, M., Komine, K., Yamada, H., Kasahara, Y., Chikamatsu, S., Okita, A., Ito, S.-E. A., Ouchi, K., Okada, Y., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0179694 · Cited by 114
Treatment in advanced colorectal cancer: what, when and how?
Chau, I., & Cunningham, D. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605061 · Cited by 115
Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Diffuse Large B-Cell Lymphoma: An Individual Patient–Level Analysis of Multiple Randomized Trials (SEAL)
Shi, Q., Schmitz, N., Ou, F., Dixon, J. G., Cunningham, D., Pfreundschuh, M. G., Seymour, J. F., Jaeger, U., Habermann, T. M., Haïoun, C., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.77.9124 · Cited by 101
Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update Summary
Hanna, N. H., Johnson, D. H., Temin, S., & Masters, G. A. (2017) · Journal of Oncology Practice · doi:10.1200/jop.2017.026716 · Cited by 105
Biological mechanism and clinical effect of protein-bound polysaccharide K (KRESTIN®): review of development and future perspectives
Maehara, Y., Tsujitani, S., Saeki, H., Oki, E., Yoshinaga, K., Emi, Y., Morita, M., Kohnoe, S., Kakeji, Y., Yano, T., et al. (2011) · Surgery Today · doi:10.1007/s00595-011-0075-7 · Cited by 96
Comparing Physician and Nurse Eastern Cooperative Oncology Group Performance Status (ECOG-PS) Ratings as Predictors of Clinical Outcomes in Patients with Cancer
Neeman, E., Gresham, G. K., Ovasapians, N., Hendifar, A. E., Tuli, R., Figlin, R. A., & Shinde, A. M. (2019) · The Oncologist · doi:10.1634/theoncologist.2018-0882 · Cited by 86
Objective assessment of WHO/ECOG performance status
Sok, M., Zavrl, M., Greif, B., & Srpčič, M. (2019) · Supportive Care in Cancer · doi:10.1007/s00520-018-4597-z · Cited by 84
Treatment of Metastatic Colorectal Cancer
Davies, J. M., & Goldberg, R. M. (2011) · Seminars in Oncology · doi:10.1053/j.seminoncol.2011.05.009 · Cited by 86
Self-citation
Molecular markers and biological targeted therapies in metastatic colorectal cancer: expert opinion and recommendations derived from the 11th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2009
Cutsem, E. V., Dicato, M. A., Arber, N., Berlin, J. D., Cervantes, A. M. R., Ciardiello, F., de Gramont, A., Díaz‐Rubio, E., Ducreux, M. P., Geva, R., et al. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq273 · Cited by 80
Self-citation
Simplified Prognostic Model in Patients with Oxaliplatin-Based or Irinotecan-Based First-Line Chemotherapy for Metastatic Colorectal Cancer: A GERCOR Study
Chibaudel, B., Bonnetain, F., Tournigand, C., Bengrine-Lefèvre, L., Teixeira, L., Artru, P., Desrame, J., Larsen, A. K., André, T., Louvet, C., et al. (2011) · The Oncologist · doi:10.1634/theoncologist.2011-0039 · Cited by 80
Self-citation
A Validated Risk Score for Venous Thromboembolism Is Predictive of Cancer Progression and Mortality
Kuderer, N. M., Culakova, E., Lyman, G. H., Francis, C. W., Falanga, A., & Khorana, A. A. (2016) · The Oncologist · doi:10.1634/theoncologist.2015-0361 · Cited by 69
The Effects of Palliative Chemotherapy in Metastatic Colorectal Cancer Patients With an ECOG Performance Status of 3 and 4
Teixeira, M. C., Marques, D. F., Ferrari, A., Alves, M. F. S., Alex, A. K., Sabbaga, J., Hoff, P. M., & Riechelmann, R. P. (2014) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2014.09.010 · Cited by 64
Nutritional and inflammatory measures predict survival of patients with stage IV colorectal cancer
Takamizawa, Y., Shida, D., Boku, N., Nakamura, Y., Ahiko, Y., Yoshida, T., Tanabe, T., Takashima, A., & Kanemitsu, Y. (2020) · BMC Cancer · doi:10.1186/s12885-020-07560-3 · Cited by 58
Colon Cancer
Benson, A. B., Arnoletti, J. P., Bekaii‐Saab, T., Chan, E. W., Chen, Y., Choti, M. A., Cooper, H. S., Dilawari, R. A., Engstrom, P. F., Enzinger, P. C., et al. (2011) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2011.0104 · Cited by 56
Self-citation
Prognostic value of systemic inflammation and for patients with colorectal cancer cachexia
Ruan, G., Xie, H., Yuan, K., Lin, S., Zhang, H., Liu, C., Shi, J., Ge, Y., Song, M., Hu, C., et al. (2023) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.13358 · Cited by 53
n-3 polyunsaturated fatty acid supplementation during cancer chemotherapy
Morland, S. L., Martins, K. J. B., & Mazurak, V. C. (2016) · Journal of Nutrition & Intermediary Metabolism · doi:10.1016/j.jnim.2016.05.001 · Cited by 53
Systematic Review of Inclusion and Analysis of Older Adults in Randomized Controlled Trials of Medications Used to Treat Inflammatory Bowel Diseases
Kochar, B. D., Kalasapudi, L., Ufere, N. N., Nipp, R. D., Ananthakrishnan, A. N., & Ritchie, C. S. (2021) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izab052 · Cited by 49
Phase I Study of Cetuximab, Irinotecan, and Vandetanib (ZD6474) as Therapy for Patients with Previously Treated Metastastic Colorectal Cancer
Meyerhardt, J. A., Ancukiewicz, M., Abrams, T. A., Schrag, D., Enzinger, P. C., Chan, J. A.-W., Kulke, M. H., Wolpin, B. M., Goldstein, M., Blaszkowsky, L. S., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0038231 · Cited by 48
Metastatic Colorectal Cancer in the Era of Personalized Medicine: A More Tailored Approach to Systemic Therapy
Yu, I. S., & Cheung, W. Y. (2018) · Canadian Journal of Gastroenterology and Hepatology · doi:10.1155/2018/9450754 · Cited by 47
Clinical, laboratory and molecular factors predicting chemotherapy efficacy and toxicity in colorectal cancer
Chua, W. M., Kho, P. S., Moore, M. M., Charles, K. A., & Clarke, S. J. (2010) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2010.07.012 · Cited by 45
Clinical value of circulating endothelial cell levels in metastatic colorectal cancer patients treated with first-line chemotherapy and bevacizumab
Malka, D., Boige, V., Jacques, N., Vimond, N., Adenis, A., Boucher, É., Pierga, J., Conroy, T., Chauffert, B., François, É., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr365 · Cited by 46
Fatigue and weight loss predict survival on circadian chemotherapy for metastatic colorectal cancer
Innominato, P. F., Giacchetti, S., Moreau, T., Bjarnason, G. A., Smaaland, R., Focan, C., Garufi, C., Iacobelli, S., Tampellini, M., Tumolo, S., et al. (2013) · Cancer · doi:10.1002/cncr.28072 · Cited by 44
Stereotactic Body Radiotherapy for Lung Metastases from Colorectal Cancer
Qiu, H., Katz, A. W., Chowdhry, A. K., Usuki, K. Y., Singh, D. P., Metcalfe, S. K., Cheruvu, P., Chen, Y., Okunieff, P. G., & Milano, M. T. (2015) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000000220 · Cited by 42
Differential toxicity biomarkers for irinotecan- and oxaliplatin-containing chemotherapy in colorectal cancer
Cortejoso, L., García, M. I., Alfonso, P. G., González-Haba, E., Escolar, F., Sanjurjo‐Sáez, M., & López-Fernández, L. A. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2145-6 · Cited by 41
Treatment of patients with metastatic colorectal cancer and poor performance status: current evidence and challenges
Rocha, L. S. D. S., & Riechelmann, R. P. (2018) · Clinics · doi:10.6061/clinics/2018/e542s · Cited by 39
Do patients with reduced or excellent performance status derive the same clinical benefit from novel systemic cancer therapies? A systematic review and meta-analysis
Cheng, S., Qureshi, M. I., Pullenayegum, E., Haynes, A. E., & Chan, K. (2017) · ESMO Open · doi:10.1136/esmoopen-2017-000225 · Cited by 39
Frailty screening for predicting rapid functional decline, rapid progressive disease, and shorter overall survival in older patients with gastrointestinal cancer receiving palliative chemotherapy - a prospective, clinical study
Jespersen, E., Winther, S. B., Minet, L. R., Möller, S., & Pfeiffer, P. (2020) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2020.10.007 · Cited by 38
A prospective study on survival in cancer patients with and without venous thromboembolism
Agnelli, G., Verso, M., Mandalà, M., Gallus, S., Cimminiello, C., Apolone, G., Minno, G. D., Maiello, E., Prandoni, P., Santoro, A., et al. (2013) · Internal and Emergency Medicine · doi:10.1007/s11739-013-0985-z · Cited by 35
Clinical Outcome of Biliary Drainage for Obstructive Jaundice Caused by Colorectal and Gastric Cancers
Kasuga, A., Ishii, H., Ozaka, M., Matsusaka, S., Chìn, K., Mizunuma, N., Yukisawa, S., Matsueda, K., & Furuse, J. (2012) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hys168 · Cited by 34
Prognostic value of preoperative inflammation-based prognostic scores in patients with stage IV colorectal cancer who undergo palliative resection of asymptomatic primary tumors.
Maeda, K., Shibutani, M., Otani, H., Nagahara, H., Sugano, K., Ikeya, T., Amano, R., Kimura, K., Sakurai, K., Kubo, N., et al. (2013) · PubMed · Cited by 34
Preoperative Physical Activity Predicts Surgical Outcomes Following Lung Cancer Resection
Billè, A., Buxton, J., Viviano, A., Gammon, D., Veres, L., Routledge, T., Harrison‐Phipps, K., Dixon, A., & Minetto, M. A. (2021) · Integrative Cancer Therapies · doi:10.1177/1534735420975853 · Cited by 32
Prognostic impact of performance status on the outcomes of immune checkpoint inhibition strategies in patients with dMMR/MSI-H metastatic colorectal cancer
Mazzoli, G., Cohen, R., Lonardi, S., Corti, F., Élez, E., Fakih, M., Jayachandran, P., Colle, R., Shah, A. T., Salati, M., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.05.044 · Cited by 32
Efficacy of immunotherapy in mismatch repair-deficient advanced colorectal cancer in routine clinical practice. An AGEO study
Alouani, E. L., Mercier, M., Flecchia, C., Auclin, É., Hollebecque, A., Mazard, T., Turpin, A., Pernot, S., Cohen, R., Dutherage, M., et al. (2023) · ESMO Open · doi:10.1016/j.esmoop.2023.101574 · Cited by 29
BRAF Mutations Are Associated with Poor Survival Outcomes in Advanced-stage Mismatch Repair-deficient/Microsatellite High Colorectal Cancer
Tan, E. S., Whiting, J., Xie, H., Imanirad, I., Carballido, E. M., Felder, S. I., Frakes, J. M., Mo, Q., Walko, C. M., Permuth, J. B., et al. (2022) · The Oncologist · doi:10.1093/oncolo/oyab055 · Cited by 30
Revisiting the Association of ECOG Performance Status With Clinical Outcomes in Diverse Patients With Cancer
Kumar, D., Neeman, E., Zhu, S., Sun, H., Kotak Dinesh, M., & Liu, R. (2024) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2023.7111 · Cited by 27
Performance Status and Its Changes Predict Outcome for Patients With Inoperable Stage III NSCLC Undergoing Multimodal Treatment
Käsmann, L., Taugner, J., Eze, C., Roengvoraphoj, O., Dantes, M., Gennen, K., Karin, M., Petrukhnov, O., Tufman, A., Belka, C., et al. (2019) · Anticancer Research · doi:10.21873/anticanres.13701 · Cited by 27
A framework for evaluating clinical artificial intelligence systems without ground-truth annotations
Kiyasseh, D., Cohen, A., Jiang, C., & Altieri, N. (2024) · Nature Communications · doi:10.1038/s41467-024-46000-9 · Cited by 26
The role of anti-epidermal growth factor receptor monoclonal antibody monotherapy in the treatment of metastatic colorectal cancer
Bouché, O., Beretta, G. D., Alfonso, P., & Geißler, M. (2010) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(10)00036-8 · Cited by 27
The Clinical Frailty Scale as predictor of overall survival after resection of high-grade glioma
Klingenschmid, J., Krigers, A., Pinggera, D., Kerschbaumer, J., Thomé, C., & Freyschlag, C. F. (2022) · Journal of Neuro-Oncology · doi:10.1007/s11060-022-04001-y · Cited by 25
The association between wearable device metrics and clinical outcomes in oncology: A systematic review with evidence synthesis and meta-analysis
Kos, M., Brouwer, C. G., van Laarhoven, H. W. M., Hopman, M. T. E., van Oijen, M. G. H., & Buffart, L. M. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.103979 · Cited by 24
Clinical outcomes of biliary drainage of malignant biliary obstruction due to colorectal cancer metastases: A systematic review
Kastelijn, J. B., van der Loos, M. A., Welsing, P. M. J., Dhondt, E., Koopman, M., Moons, L. M. G., & Vleggaar, F. P. (2021) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2021.03.032 · Cited by 22
The association between body mass index and efficacy of pembrolizumab as second‐line therapy in patients with recurrent/metastatic head and neck squamous cell carcinoma
Zhang, X., Rui, M., Lin, C., Li, Z., Wei, D., Han, R., Ju, H., & Ren, G. (2022) · Cancer Medicine · doi:10.1002/cam4.5152 · Cited by 22
A Natural Language Processing Algorithm to Improve Completeness of ECOG Performance Status in Real-World Data
Cohen, A. B., Rosic, A., Harrison, K., Richey, M., Nemeth, S., Ambwani, G., Miksad, R. A., Haaland, B. A., & Jiang, C. (2023) · Applied Sciences · doi:10.3390/app13106209 · Cited by 24
The real‐world clinical outcomes and treatment patterns of patients with unresectable locally advanced or metastatic soft tissue sarcoma treated with anlotinib in the post‐ALTER0203 trial era
Zhang, R., Liu, J., Deng, Y., Wu, X. Y., & Jiang, Y. (2022) · Cancer Medicine · doi:10.1002/cam4.4613 · Cited by 21
Associations and prognostic implications of Eastern Cooperative Oncology Group performance status and tumoral LINE-1 methylation status in stage III colon cancer patients
Chen, D., Wen, X., Song, Y. S., Rhee, Y.-Y., Lee, T. H., Cho, N., Han, S., Kim, T., & Kang, G. H. (2016) · Clinical Epigenetics · doi:10.1186/s13148-016-0203-8 · Cited by 20
The association between wearable activity monitor metrics and performance status in oncology: a systematic review
Kos, M., Pijnappel, E. N., Buffart, L. M., Balvers, B. R., Kampshoff, C. S., Wilmink, J. W., van Laarhoven, H. W. M., & van Oijen, M. G. H. (2021) · Supportive Care in Cancer · doi:10.1007/s00520-021-06234-5 · Cited by 20
Eligibility for CAR T‐cell therapy: An analysis of selection criteria and survival outcomes in chemorefractory DLBCL
Smith, S. D., Reddy, P., Sokolova, A. O., Chow, V. A., Lynch, R. C., Shadman, M. S., Till, B. G., Shustov, A. R., Warren, E. H., Ujjani, C. S., et al. (2019) · American Journal of Hematology · doi:10.1002/ajh.25411 · Cited by 20
A phase II, randomized, double blind trial of calcium aluminosilicate clay versus placebo for the prevention of diarrhea in patients with metastatic colorectal cancer treated with irinotecan
Kee, B. K., Morris, J. S., Slack, R. S., Crocenzi, T. S., Wong, L., Esparaz, B., Overman, M. J., Glover, K. Y., Jones, D., Wen, S., et al. (2014) · Supportive Care in Cancer · doi:10.1007/s00520-014-2402-1 · Cited by 20
Feasibility of Fitness Tracker Usage to Assess Activity Level and Toxicities in Patients With Colorectal Cancer
Ward, W. H., Meeker, C. R., Handorf, E. R., Hill, M. V., Einarson, M. B., Alpaugh, R. K., Holden, T. L., Astsaturov, I. A., Denlinger, C. S., Hall, M. J., et al. (2021) · JCO Clinical Cancer Informatics · doi:10.1200/cci.20.00117 · Cited by 19
Physical function and quality of life in frail and/or elderly patients with metastatic colorectal cancer treated with capecitabine and bevacizumab: An exploratory analysis
Ward, P., Hecht, J. R., Wang, H.-J., Dichmann, R., Liem, A. K. D., Chan, D., Patel, R., Hu, E. H. L., Tchekmedyian, N. S., Wainberg, Z. A., et al. (2014) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2014.05.002 · Cited by 18
Progression-free survival in first-line chemotherapy is a prognostic factor in second-line chemotherapy in patients with advanced gastric cancer
Hashimoto, K., Takashima, A., Nagashima, K., Okazaki, S.-S., Nakajima, T. E., Kato, K., Hamaguchi, T., Yamada, Y., & Shimada, Y. (2009) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-009-0752-8 · Cited by 18
Primary resistance to immunotherapy in patients with a dMMR/MSI metastatic gastrointestinal cancer: who is at risk? An AGEO real-world study
Flecchia, C., Auclin, É., Alouani, E. L., Mercier, M., Hollebecque, A., Turpin, A., Mazard, T., Pernot, S., Dutherage, M., Cohen, R., et al. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02524-3 · Cited by 18
Analysis of Heterogeneity in Survival Benefit of Immunotherapy in Oncology According to Patient Demographics and Performance Status
Butaney, M., Satkunasivam, R., Goldberg, H., Freedland, S. J., Patel, S. P., Hamid, O., Pal, S. K., Klaassen, Z. W. A., & Wallis, C. J. D. (2019) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000000650 · Cited by 17
Current and New Predictors for Treatment Response in Metastatic Colorectal Cancer. The Role of Circulating miRNAs as Biomarkers
Gherman, A., Bălăcescu, L., Cetean, S., Vlad, C. I., Bălăcescu, O., Irimie, A., & Lisencu, C. I. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21062089 · Cited by 17
Effectiveness and Safety of Intensive Triplet Chemotherapy Plus Bevacizumab, FIr-B/FOx, in Young-Elderly Metastatic Colorectal Cancer Patients
Bruera, G., Cannita, K., Giordano, A. V., Vicentini, R., Ficorella, C., & Ricevuto, E. (2013) · BioMed Research International · doi:10.1155/2013/143273 · Cited by 17
Meaningful measures in cancer cachexia: implications for practice and research
McDonald, J. J., Fallon, M., & Laird, B. J. A. (2019) · Current Opinion in Supportive and Palliative Care · doi:10.1097/spc.0000000000000472 · Cited by 15
Scientific and Clinical Challenges within Neuro-Oncology
Barbaro, M., Fine, H. A., & Magge, R. (2021) · World Neurosurgery · doi:10.1016/j.wneu.2021.01.151 · Cited by 15
How to integrate molecular targeted agents in the continuum of care
Köhne, C.-H. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq374 · Cited by 14
Self-citation
Development and validation of a claims-based approach to proxy ECOG performance status across ten tumor groups
Sheffield, K. M., Bowman, L., Smith, D. M., Li, L., Hess, L. M., Montejano, L. B., Willson, T. M., & Davidoff, A. J. (2018) · Journal of Comparative Effectiveness Research · doi:10.2217/cer-2017-0040 · Cited by 14
A Nomogram for Predicting Risk of Thromboembolism in Gastric Cancer Patients Receiving Chemotherapy
Yuan, H.-L., Zhang, X., Yan, L., Guan, Q., Chu, W., Yu, H., Liu, L., Zheng, Y., & Lu, J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.598116 · Cited by 14
Safety and efficacy of weekly 5-fluorouracil/ folinic acid/oxaliplatin/irinotecan in the first-line treatment of gastrointestinal cancer
Peinert, S., Grothe, W., Stein, A., Müller, L. P., Ruessel, J., Voigt, W., Schmoll, H., & Arnold, D. (2010) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834010365061 · Cited by 14
Chemotherapy for advanced cancers.
Rajagopal, P. S., Nipp, R. D., & Selvaggi, K. J. (2014) · PubMed · doi:10.3978/j.issn.2224-5820.2014.06.02 · Cited by 14
Real-World Treatment and Outcomes of Metastatic Colorectal Cancer Patients With a Poor or Very Poor Performance Status
Travers, A., Jalali, A., Begbie, S. D., Semira, C., Kosmider, S., Ananda, S. S., Wong, R., Lee, M., Shapiro, J. D., Burge, M., et al. (2020) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2020.08.002 · Cited by 13
How we treat metastatic colon cancer in older adults
Sanoff, H. K., & Goldberg, R. M. (2013) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2013.07.007 · Cited by 13
Self-citation
Prognostic factors in patients with non resectable metastatic colorectal cancer in the era of targeted biotherapies: Relevance of Köhne's risk classification
Desot, E., de Mestier, L., Volet, J., Delmas, C., Garcia, B., Geoffroy, P., Abdelli, N., Baule, M., Dubroeucq, O., Marquis, E., et al. (2012) · Digestive and Liver Disease · doi:10.1016/j.dld.2012.10.016 · Cited by 13
Prognostic factors for 60-day mortality in first-line treatment of metastatic colorectal cancer (mCRC): individual patient analysis of four randomised, controlled trials by the AIO colorectal cancer study group
Giessen, C. A., Graeven, U., Laubender, R. P., Modest, D. P., Schulz, C. U., Porschen, R., Schmiegel, W., Reinacher‐Schick, A., Hegewisch-Becker, S., Stintzing, S., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt402 · Cited by 13
Self-citation
Risk factors for postoperative delirium in patients with colorectal cancer
Kim, H., Park, H., & Kim, E. K. (2021) · Journal of Clinical Nursing · doi:10.1111/jocn.15894 · Cited by 12
Efficacy and toxicity of weekly paclitaxel, carboplatin, and cetuximab as induction chemotherapy or in cases of metastases or relapse for head and neck cancer with a focus on elderly or frail patients
Forman, R., Deshpande, H. A., Burtness, B. A., & Bhatia, A. K. (2022) · Head & Neck · doi:10.1002/hed.27077 · Cited by 13
Prognostic relevance of KRAS genotype in metastatic colorectal cancer patients unfit for FIr-B/FOx intensive regimen
Bruera, G., Cannita, K., Giordano, A. V., Vicentini, R., Ficorella, C., & Ricevuto, E. (2014) · International Journal of Oncology · doi:10.3892/ijo.2014.2369 · Cited by 12
Clinical parameters to guide decision-making in elderly metastatic colorectal cancer patients treated with intensive cytotoxic and anti-angiogenic therapy
Bruera, G., Russo, A. D., Galvano, A., Rizzo, S., & Ricevuto, E. (2016) · Oncotarget · doi:10.18632/oncotarget.14333 · Cited by 12
Performance status as prognostic factor in phase III trials of first‐line chemotherapy of unresectable or metastatic pancreatic cancer: A trial‐level meta‐analysis
Colloca, G. A. (2021) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.13598 · Cited by 11
Palliative Rehabilitation in Acute Inpatient Rehabilitation: Prognostic Factors and Functional Outcomes in Patients with Cancer
Tennison, J. M., Asher, A., Hui, D., Javle, M. M., Bassett, R. L., & Bruera, E. D. (2022) · The Oncologist · doi:10.1093/oncolo/oyac229 · Cited by 11
Optimizing the first-line treatment for metastatic colorectal cancer
Cherri, S., Oneda, E., Zanotti, L., & Zaniboni, A. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1246716 · Cited by 16
Palliative Treatment of Colorectal Cancer with Secondary Metastasis Resection in Germany - Impact of the Multidisciplinary Treatment Approach on Prognosis and Cost: The Northern Bavaria IVOPAK I Project
Wein, A., Emmert, M., Merkel, S., Harich, H., Siebler, J., Thiemann, R., Lamberti, C., Göttler, B., Fries, S., Kiani, A., et al. (2014) · Oncology · doi:10.1159/000368246 · Cited by 11
From Shelf to Bedside—Wearable Electronic Activity Monitoring Technologies Might Assist Oncologists in Functional Performance Status Assessment of Older Cancer Patients
Kelly, C. M., & Shahrokni, A. (2016) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2016.11.002 · Cited by 11
NCCTG Study N9741: Leveraging Learning from an NCI Cooperative Group Phase III Trial
Goldberg, R. M., Sargent, D. J., Morton, R. F., Green, E., Sanoff, H. K., McLeod, H. L., & Buckner, J. C. (2009) · The Oncologist · doi:10.1634/theoncologist.2009-0175 · Cited by 11
Self-citation
Prognostic Effect of Performance Status on Outcomes of Patients with Colorectal Cancer Receiving First-Line Chemotherapy: A Meta-analysis
Colloca, G. A., & Venturino, A. (2023) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-023-00983-8 · Cited by 10
Remote Monitoring of the Performance Status and Burden of Symptoms of Patients With Gastrointestinal Cancer Via a Consumer-Based Activity Tracker: Quantitative Cohort Study
Ghods, A., Shahrokni, A., Ghasemzadeh, H. G., & Cook, D. J. (2021) · JMIR Cancer · doi:10.2196/22931 · Cited by 10
Clinical Predictors of Early Mortality in Colorectal Cancer Patients Undergoing Chemotherapy: Results From a Global Prospective Cohort Study
Sohal, D. P. S., Kuderer, N. M., Shepherd, F. A., Pabinger, I., Agnelli, G., Liebman, H. A., Meyer, G., Kalady, M. F., McCrae, K. R., Lyman, G. H., et al. (2017) · JNCI Cancer Spectrum · doi:10.1093/jncics/pkx009 · Cited by 10
Integrating Frailty Assessment to Enhance Care in Cancer Patients with Borderline Eastern Cooperative Oncology Group Performance Status
Hsu, C., Hung, Y., Yu, S., Hsueh, S., & Chou, W. (2024) · American Journal of Hospice and Palliative Medicine® · doi:10.1177/10499091231226062 · Cited by 9
Influence of the skeletal muscle index on pharmacokinetics and toxicity of fluorouracil
Schmulenson, E., Zimmermann, N., Müller, L., Kapsa, S., Sihinevich, I., & Jaehde, U. (2022) · Cancer Medicine · doi:10.1002/cam4.5118 · Cited by 9
Performance Status and Resilience in Patients with Colorectal Cancer
Lee, E., Yoon, J. H., Park, D., & Park, D. (2013) · Asian Oncology Nursing · doi:10.5388/aon.2013.13.4.273 · Cited by 9
Prognostic relevance of distant metastases versus locally advanced disease in soft tissue sarcomas: An EORTC-STBSG database study
Verschoor, A. J., Litière, S., Marreaud, S. I., Judson, I. R., Toulmonde, M., Wardelmann, E., van der Graaf, W. T. A., Cesne, A. L., Gronchi, A., & Gelderblom, H. A. J. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.02.015 · Cited by 9
Management of chemotherapy dose intensity for metastatic colorectal cancer (Review)
Chu, X., Xue, P., & Zhu, S. (2022) · Oncology Letters · doi:10.3892/ol.2022.13261 · Cited by 9

Authors: Sargent, D. J., Köhne, C. H., Sanoff, H. K., Bot, B. M., Seymour, M. T., de Gramont, A., Porschen, R., Saltz, L. B., Rougier, P., Tournigand, C., Douillard, J.-Y., Stephens, R. J., Grothey, A., & Goldberg, R. M.
Affiliations: University of North Carolina at Chapel Hill (US)
From the Mayo Clinic, Rochester, MN; University of North Carolina, Chapel Hill, NC; Memorial Sloan-Kettering Cancer Center, New York, NY; Klinikum Oldenburg, Oldenburg; Klinikum Bremen, Bremen, Germany; Cancer Research Center UK Clinical Centre, Leeds; Medical Research Council, London, United Kingdom; Hopital Saint Antoine, Paris; Hopital Ambroise Pare, Boulogne; and Center R. Gauducheau, St Herblain, France.
ORCID: Sargent, Daniel J.
Sanoff, Hanna Kelly
Bot, Brian M.
Saltz, Leonard B.
Douillard, Jean-Yves
Stephens, Richard J.
Goldberg, Richard M.
Venue: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Published: 2009-04-20
Volume: 27
Issue: 12
Pages: 1948-1955
ISSN: 0732-183X (ISSN-L)
1527-7755
DOI: 10.1200/jco.2008.20.2879
PMC: PMC2669760
OpenAlex: W2101472517
Cited by: 196
References: 32
Citations by year: 2026: 6 · 2025: 9 · 2024: 7 · 2023: 14 · 2022: 20 · 2021: 15 · 2020: 10 · 2019: 9 · 2018: 12 · 2017: 6 · 2016: 8 · 2015: 8 · 2014: 13 · 2013: 16 · 2012: 9
FWCI: 6.99
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Journal of Clinical Oncology (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Funders: Amgen
Bristol-Myers Squibb
Pfizer
Sanofi
American Society of Clinical Oncology
Celgene
Taiho Pharmaceutical
Genentech
National Cancer Institute ((CA-25224, U10CA025224)
Topics: Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
Health Sciences › Medicine › Surgery › Intraperitoneal and Appendiceal Malignancies
Keywords: metastatic colorectal cancer, performance status, first-line chemotherapy, prognostic factors, progression-free survival, overall survival, treatment toxicity, nausea and vomiting, all-cause mortality, combination chemotherapy, individual patient data
MeSH terms: Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Female, Humans, Male, Middle Aged, Prognosis, Retrospective Studies, Colorectal Neoplasms, Survival Rate, Treatment Outcome, Clinical Trials, Phase III as Topic, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Pooled Safety and Efficacy Analysis Examining the Effect of Performance Status on Outcomes in Nine First-Line Treatment Trials Using Individual Data From Patients With Metastatic Colorectal Cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks